Anderman Jonathan 4

What Happened Jonathan Anderman, General Counsel of Compass Therapeutics (CMPX), was granted 25,000 shares on 2026-04-29 reported at $1.89 per share, a total reported value of $47,250. The filing shows this as an award/grant (transaction code A), not an open-market purchase or sale — i.e., compensation rather than a cash purchase.

Key Details

• Transaction date and type: 2026-04-29 — Award/Grant (Code A).
• Shares and value: 25,000 shares at $1.89 per share; total reported value $47,250.
• Shares owned following transaction: Not disclosed in the filing.
• Footnote (F1): The filing notes 150,000 of the shares are unvested restricted stock units (RSUs) granted on January 2, 2026; each RSU is a contingent right to one share and vests in four equal annual installments, with the first vesting on January 2, 2027.
• Timeliness: Report period and filing date are both 2026-04-29 (timely filing).
• No 10b5-1 plan, tax withholding, or immediate sale reported in this transaction.

Context This was an RSU award (compensation) rather than a market purchase; RSUs are subject to vesting and typically do not reflect an immediate investment of personal cash. Awards are common executive compensation and should be interpreted differently from insider purchases or sales — they disclose potential future share issuance contingent on service/vesting.